Daisy Genomics Inc.

Daisy Genomics Inc. , based in the US, specializes in innovative genomic analysis solutions, focusing on advanced technology that enhances precision in research and diagnostics within the biotechnology sector. Founded in 2017 and headquartered in Carlsbad, US, Daisy Genomics Inc. offers a unique approach to genomic analysis.

The company has successfully completed 2 deals and raised a total of USD 2. 5 mn through its Seed funding round on December 23, 2025, which included participation from investors such as Cottonwood Technology Fund, Tramway Venture Partners, and WaveStone Capital. The founder's background is not detailed in the available information. Daisy Genomics Inc.

provides advanced genomic analysis solutions designed to fill critical gaps in genomics research and diagnostics. Their proprietary platform utilizes Surface Enhanced Raman Spectroscopy (SERS) technology to detect single nucleotides without DNA amplification, labels, or library preparation. This method allows for the identification of essential epigenetic data and genomic markers that traditional methods may overlook. Their technology is particularly beneficial for research institutions and healthcare organizations, especially in North America and Europe, where precision medicine is increasingly important.

Daisy Genomics Inc. generates its revenue primarily through direct B2B transactions with research institutions, biotech firms, and healthcare providers. The company engages in partnerships and licensing agreements that enable clients to utilize their advanced genomic analysis technology for various research and diagnostic tasks. Pricing is tailored according to the specific needs and project scopes of their clients, reflecting the value of their innovative genomic analysis capabilities.

With the recent Seed funding of USD 2. 5 mn, Daisy Genomics Inc. plans to further develop its sequencing platform and enhance chip performance. The company aims to broaden its research network and build partnerships with universities and related organizations, with particular emphasis on expanding its market reach in North America and Europe by 2026.